血清肿瘤标志物CA125及^(18)F-FDG PET/CT造影在卵巢癌复发早期诊断中的价值

Value of serum tumor markers CA125 and ^(18)F-FDG PET/CT in early diagnosis of recurrence of ovarian cancer

目的探讨血清肿瘤标志物CA125、^(18)F-FDG PET/CT及两者联合检测在卵巢癌复发早期诊断中的价值。方法 2016年3月至2017年6月,对41例疑似复发的卵巢癌术后患者行^(18)F-FDG PET/CT造影和血清CA125检测,随访复发转移灶,并以病理检查结果为金标准计算灵敏度、特异度、诊断符合率、阳性预测值和阴性预测值。结果根据病理结果诊断为卵巢癌复发、转移的共36例。CA125对卵巢癌复发、转移诊断的灵敏度、特异度、诊断符合率、阳性预测值和阴性预测值分别为91.7%(33/36)、80.0%(4/5)、90.2%(37/41)、97.1%(33/34)、57.1%(4/7);^(18)F-FDG PET/CT对卵巢癌复发、转移诊断的灵敏度、特异度、诊断符合率、阳性预测值和阴性预测值分别为97.2%(35/36)、80.0%(4/5)、95.1%(39/41)、97.2%(35/36)、80.0%(4/5);两者联合检测对卵巢癌复发、转移诊断的灵敏度、特异度、诊断符合率、阳性预测值和阴性预测值分别为100.0%(36/36)、80.0%(4/5)、97.6%(40/41)、97.3%(36/37)、100.0%(4/4)。^(18)F-FDG PET/CT对卵巢癌复发、转移诊断的灵敏度、诊断符合率和阴性预测值均高于CA125;两者联合检测的灵敏度和阴性预测值均高于CA125和^(18)F-FDG PET/CT单独检测。结论血清肿瘤标志物CA125联合^(18)F-FDG PET/CT检测卵巢癌复发情况的效果良好,值得临床应用。

Objective To investigate the value of serum tumor markers CA125,18F-FDG PET/CT and their combined detection in early diagnosis of ovarian cancer recurrence. Methods From March 2016 to June 2017, 41 patients with suspected recurrent ovarian cancer were given18F-FDG PET/CT imaging and serum CA125 detection, and recurrence metastasis were followed up. The pathological examination result was used as the gold standard to calculate sensitivity,specificity, diagnostic coincidence rate, positive predictive value and negative predictive value. Results Thirty-six cases of ovarian cancer recurrence and metastasis were diagnosed according to pathological findings. The sensitivity, specificity,diagnostic coincidence rate, positive predictive value and negative predictive value of CA125 in diagnosis of ovarian cancer recurrence and metastasis were 91.7%(33/36), 80.0%(4/5), 90.2%(37/41), 97.1%(33/34) and 57.1%(4/7), respectively.The sensitivity, specificity, diagnostic coincidence rate, positive predictive value and negative predictive value of18F-FDG PET/CT in diagnosis of ovarian cancer recurrence and metastasis were 97.2%(35/36), 80.0%(4/5), 95.1%(39/41), 97.2%(35/36) and 80.0%(4/5), respectively. The sensitivity, specificity, diagnostic coincidence rate, positive predictive value and negative predictive value of combined detection were 100.0%(36/36), 80.0%(4/5), 97.6%(40/41), 97.3%(36/37) and100.0%(4/4), respectively. The sensitivity, diagnostic coincidence rate and negative predictive value of18F-FDG PET/CT in diagnosis of ovarian cancer recurrence and metastasis were higher than those of CA125. The sensitivity and negative predictive value of combined detection were higher than those of CA125 and18F-FDG PET/CT alone. Conclusion Serum tumor markers CA125 combined with18F-FDG PET/CT has a good effect in detecting the recurrence of ovarian cancer,which is worthy of clinical application.